3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioma
3
Glioblastoma
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Brain Neoplasms
2
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Interventions
Radiotherapy
83
Temozolomide
78
Filgrastim
34
Carboplatin
33
Vincristine
29
Etoposide
26
Cyclophosphamide
25
Carmustine
25
Irinotecan
23
Chemotherapy, Adjuvant
23
Cisplatin
21
Peripheral Blood Stem Cell Transplantation
20
Thiotepa
14
Lomustine
14
Granulocyte Colony-Stimulating Factor
13
Surgical Procedures, Operative
12
Procarbazine
12
Bevacizumab
11
Thalidomide
10
O(6)-benzylguanine
10
Drug Therapy
10
etoposide phosphate
9
Methotrexate
9
Magnetic Resonance Spectroscopy
9
Gene Expression Profiling
9
Radiation
8
Paclitaxel
8
sargramostim
7
Ifosfamide
7
Everolimus
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Central Nervous System Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled